Latest News - Retina

Thursday, February 15, 2018 | Medical Studies, Retina, Diabetes

Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema

In patients with diabetic macular edema (DME), aflibercept and ranibizumab are more effective than bevacizumab in preventing disease persistence, but each drug can lead to substantial gains in vision,…

Read the full story

Tuesday, February 13, 2018 | Medical Studies, Retina

Award Winning Algorithm Could Improve Accuracy and Speed of Diagnosis of Retinal Disease

A new technique for identifying and diagnosing damage to the human retina has been awarded ‘Best Student Paper’ at the industry-leading BIOIMAGING 2018 conference in Portugal, according to…

Read the full story

Monday, February 12, 2018 | Clinical Trials, Retina, Aerpio Therapeutics

Aerpio Pharmaceuticals Completes Patient Enrollment in a Phase 2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy

Aerpio Pharmaceuticals announced the completion of patient enrollment in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead …

Read the full story

Monday, February 12, 2018 | Clinical Trials, Retina, Santen

Santen Presents Phase 1/2 Data on DE-122 (Carotuximab) in Patients with Refractory Wet AMD

Santen announced that the topline results from the phase 1/2 study of DE-122 (carotuximab) for refractory wet age-related macular degeneration (AMD) were presented at the 15th Annual Angiogenesis, Exu…

Read the full story

Monday, February 12, 2018 | Clinical Trials, Retina, AMD

Phase 2 Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People with DME

Genentech announced encouraging results from the phase 2 BOULEVARD study. In people with vision loss from diabetic macular edema (DME), treatment with intravitreal RG7716 demonstrated clinically meani…

Read the full story

Tuesday, February 06, 2018 | Partnerships, Retina, AMD, Bausch+Lomb

Bausch + Lomb and Prevent Blindness Encourage People to Fight for Their Sight During February and AMD Awareness Month

Bausch + Lomb announced the launch of a public service announcement and docu-series designed to raise awareness of age-related macular degeneration (AMD). The series includes deeply powerful stories o…

Read the full story

Tuesday, January 30, 2018 | Product Releases, Retina, AMD

Eyepromise Introduces New Formula of Eyepromise Restore for Patients with Early Signs of AMD

EyePromise announced the introduction of a new and improved formula to its EyePromise Restore line, with the addition of vitamins B6 and B12, folic acid, and Coenzyme Q10 (CoQ10), according to a …

Read the full story

Thursday, January 25, 2018 | Blindness, Retina, AMD, Pixium Vision

Pixium Vision Completes World’s First Successful Activation in Human of PRIMA Bionic Vision System

Pixium Vision announced the first successful human implantation and activation of PRIMA, its new generation miniaturized wireless photovoltaic subretinal implant, in a patient with severe vision loss …

Read the full story

Thursday, January 25, 2018 | Partnerships, Retina, Novartis, Spark Therapeutics

Novartis Licenses Spark Therapeutics' Gene Therapy in All Markets Outside the US

Novartis announced a licensing agreement with Spark Therapeutics covering development, registration, and commercialization rights to voretigene neparvovec in markets outside the United States. Voretig…

Read the full story

Monday, January 22, 2018 | Awards, Retina

The Assistance Fund Opens New Program for Inherited Retinal Diseases

The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, launched a new program that offers financial supp…

Read the full story

Wednesday, January 10, 2018 | Clinical Trials, Retina, GenSight Biologics

GenSight Biologics Receives MHRA Approval to Initiate Phase 1/2 PIONEER Clinical Trial of Gene Therapy in Retinitis Pigmentosa

GenSight Biologics announced that the UK Medicines and Healthcare Regulatory Agency (MHRA) has accepted the company’s clinical trial application (CTA) to initiate the PIONEER phase 1/2 study of …

Read the full story

Monday, January 08, 2018 | Retina, Psivida

pSivida Submits NDA for Durasert Three-Year Treatment for Posterior Segment Uveitis to the FDA

pSivida announced it has submitted its new drug application (NDA) to the FDA for Durasert 3-year treatment for posterior segment uveitis. The NDA includes data from two phase 3 studies that each succe…

Read the full story

Thursday, January 04, 2018 | Earnings & Financials, Retina

Oculis Raises $20.3 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases

Oculis announced it has successfully closed a Series B financing round of CHF 20 million ($20.3 million). The funds will be used to advance the clinical development of the company’s lead program…

Read the full story

Thursday, January 04, 2018 | Retina, Alimera Sciences

Alimera Sciences Receives Acceptance of Filing to Obtain Approval for Iluvien Uveitis Indication in Europe

Alimera Sciences announced that it received validation of a Type II variation for Iluvien submitted on December 12, 2017. The Type II variation was submitted through the Mutual Recognition Procedure w…

Read the full story

Thursday, January 04, 2018 | Retina, Pixium Vision

Pixium Vision Receives FDA Approval to Begin Human Clinical Study of Its PRIMA Retinal Implant in the US

Pixium Vision announced that it has received approval from the FDA to begin the clinical feasibility study for PRIMA, Pixium Vision’s new-generation miniaturized wireless photovoltaic subretinal…

Read the full story
Load More